Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
F1000Res ; 11: 8, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36071711

RESUMO

Background: After a diet- or surgery induced weight loss almost 1/3 of lost weight consists of fat free mass (FFM) if carried out without additional therapy. Exercise training and a sufficient supply of protein, calcium and vitamin D is recommended to reduce the loss of FFM. Objective: To investigate the effect of exercise training, protein, calcium, and vitamin D supplementation on the preservation of FFM during non-surgical and surgical weight loss and of the combination of all interventions together in adults with obesity. Methods: A systematic review was performed with a pairwise meta-analysis and an exploratory network meta-analysis according to the PRISMA statement. Results: Thirty studies were included in the quantitative analysis. The pairwise meta-analysis showed for Exercise Training + High Protein vs. High Protein a moderate and statistically significant effect size (SMD 0.45; 95% CI 0.04 to 0.86), for Exercise Training + High Protein vs. Exercise Training a high but statistically not significant effect size (SMD 0.91; 95% CI -0.59 to 2.41) and for Exercise Training alone vs. Control a moderate but statistically not significant effect size (SMD 0.67; 95% CI -0.25 to 1.60). In the exploratory network meta-analysis three interventions showed statistically significant effect sizes compared to Control and all of them included the treatment Exercise Training. Conclusions: Results underline the importance of exercise training and a sufficient protein intake to preserve FFM during weight loss in adults with obesity. The effect of calcium and vitamin D supplementation remains controversial and further research are needed.


Assuntos
Composição Corporal , Cálcio , Suplementos Nutricionais , Exercício Físico , Humanos , Obesidade/terapia , Vitamina D/uso terapêutico , Redução de Peso
2.
Patient Prefer Adherence ; 16: 1733-1747, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35910298

RESUMO

Purpose: Medical decision-making in older adults with multiple chronic conditions and polypharmacy should include the individual patient's treatment preferences. We developed and pilot-tested an electronic instrument (PolyPref) to elicit patient preferences in geriatric polypharmacy. Patients and Methods: PolyPref follows a two-stage direct approach to preference assessment. Stage 1 generates an individual preselection of relevant health outcomes and medication regimen characteristics, followed by stage 2, in which their importance is assessed using the Q-sort methodology. The feasibility of the instrument was tested in adults aged ≥70 years with ≥2 chronic conditions and regular intake of ≥5 medicines. After the assessment with PolyPref, the patients rated the tool with regard to its comprehensibility and usability and assessed the accuracy of the personal result. Evaluators rated the patients' understanding of the task. Results: Eighteen short-term health outcomes, 3 long-term health outcomes, and 8 medication regimen characteristics were included in the instrument. The final population for the pilot study comprised 15 inpatients at a clinic for geriatric rehabilitation with a mean age of 80.6 (± 6.0) years, a median score of 28 (range 25-30) points on the Mini-Mental State Examination, and a mean of 11.6 (± 3.6) regularly taken medicines. Feedback by the patients and the evaluators revealed ratings in favor of understanding and comprehensibility of 86.7% to 100%. The majority of the patients stated that their final result summarized the most important aspects of their pharmacotherapy (93.3%) and that its ranking order reflected their personal opinion (100%). Preference assessment took an average of 35 (± 8.5) min, with the instrument being handled by the evaluator in 14 of the 15 participants. Conclusion: Preference assessment with PolyPref was feasible in older adults with multiple chronic conditions and polypharmacy, offering a new strategy for the standardized evaluation of patient priorities in geriatric pharmacotherapy.

3.
J Cachexia Sarcopenia Muscle ; 13(1): 264-275, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-34898035

RESUMO

BACKGROUND: The strength, assistance walking, rise from a chair, climb stairs, and falls (SARC-F) questionnaire is a well-established instrument for screening of sarcopenia and sarcopenia-related functional impairments. As it is based on self-reporting, its use precludes patients who are unable to answer the questionnaire as a consequence of severe acute diseases or cognitive impairment. Therefore, we aimed to validate a proxy-reported version of the SARC-F for both ad-hoc as well as retrospective screening for severe sarcopenia-related functional impairments. METHODS: Patients aged ≥60 years completed the SARC-F and performed the short physical performance battery (SPPB) at baseline (T1). Proxies in Cohort A gave a simultaneous assessment of the patients' functional status with the proxy-reported SARC-F at T1 and again, retrospectively, after 3 months (T2). Proxies in Cohort B only completed the SARC-F retrospectively at T2. The questionnaires' performances were assessed through sensitivity/specificity analyses and receiver operating characteristic (ROC) curves. For non-inferiority analyses, results of both the patient-reported and proxy-reported SARC-F were correlated with the SPPB total score as well as the results of the chair-rise test subcategory; the respective correlation coefficients were tested against each other. RESULTS: One hundred and four patients and 135 proxies participated. Using a SPPB score < 9 points as the reference standard, the proxy-reported SARC-F identified patients at high risk for sarcopenia-related functional impairment with a sensitivity of 0.81 (ad-hoc), 0.88 (retrospective Cohort A), and 0.87 (retrospective Cohort B) as well as a specificity of 0.89 (ad-hoc), 0.78 (retrospective Cohort A), and 0.64 (retrospective Cohort B). Areas under the ROC curves were ≥ 0.9 for the ad-hoc proxy-reported SARC-F and the retrospective proxy-reported SARC-F in both cohorts. The proxy-reported SARC-F showed a non-inferior correlation with the SPPB compared with the patient-reported SARC-F for ad-hoc (P = <0.001) as well as retrospective screening for severe sarcopenia-related functional impairment in both Cohorts A (P = 0.007) and B (P = 0.026). CONCLUSIONS: Proxy-reported SARC-F is a valid instrument for both ad-hoc as well as retrospective screening for sarcopenia-related functional impairment and could become the standard tool for evaluating this risk in older adults with severe acute disease, for example, in patients with quickly evolving haematological conditions.


Assuntos
Sarcopenia , Idoso , Estudos Transversais , Humanos , Programas de Rastreamento/métodos , Pessoa de Meia-Idade , Estudos Retrospectivos , Sarcopenia/diagnóstico , Sarcopenia/etiologia , Inquéritos e Questionários
4.
Patient Prefer Adherence ; 14: 467-497, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32184575

RESUMO

PURPOSE: The aim of this systematic review was to identify methods used to assess medication preferences in older adults and evaluate their advantages and disadvantages with respect to their applicability to the context of multimorbidity and polypharmacy. MATERIAL AND METHODS: Three electronic databases (PubMed, Web of Science, PsycINFO) were searched. Eligible studies elicited individual treatment or outcome preferences in a context that involved long-term pharmacological treatment options. We included studies with a study population aged ≥ 65 years and/or with a mean or median age of ≥ 75 years. Qualitative studies, studies assessing preferences for only two different treatments, and studies targeting preferences for life-sustaining treatments were excluded. The identified preference measurement methods were evaluated based on four criteria (time budget, cognitive demand, variety of pharmacological aspects, and link with treatment strategies) judged to be relevant for the elicitation of patient preferences in polypharmacy. RESULTS: Sixty articles met the eligibility criteria and were included in the narrative synthesis. Fifty-five different instruments to assess patient preferences, based on 24 different elicitation methods, were identified. The most commonly applied preference measurement techniques were "medication willingness" (description of a specific medication with inquiry of the participant's willingness to take it), discrete choice experiments, Likert scale-based questionnaires, and rank prioritization. The majority of the instruments were created for disease-specific or context-specific settings. Only three instruments (Outcome Prioritization Tool, a complex intervention, "MediMol" questionnaire) dealt with the broader issue of geriatric multimorbidity. Only seven of the identified tools showed somewhat favorable characteristics for a potential use of the respective method in the context of polypharmacy. CONCLUSION: Up to now, few instruments have been specifically designed for the assessment of medication preferences in older patients with multimorbidity. To facilitate valid preference elicitation in the context of geriatric polypharmacy, future research should focus on suitable characteristics of existing techniques to develop new measurement approaches for this increasingly relevant population.

5.
Science ; 340(6133): 727-30, 2013 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-23661757

RESUMO

Global sulfate production plays a key role in aerosol radiative forcing; more than half of this production occurs in clouds. We found that sulfur dioxide oxidation catalyzed by natural transition metal ions is the dominant in-cloud oxidation pathway. The pathway was observed to occur primarily on coarse mineral dust, so the sulfate produced will have a short lifetime and little direct or indirect climatic effect. Taking this into account will lead to large changes in estimates of the magnitude and spatial distribution of aerosol forcing. Therefore, this oxidation pathway-which is currently included in only one of the 12 major global climate models-will have a significant impact on assessments of current and future climate.


Assuntos
Atmosfera/química , Clima , Poeira , Dióxido de Enxofre/química , Aerossóis , Catálise , Minerais/química , Oxirredução , Elementos de Transição
6.
J Environ Monit ; 12(2): 409-16, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20145880

RESUMO

Biovolatilisation of arsenic as their arsines in the form of AsH(3), and mono-, di and trimethylarsine has often been determined under laboratory conditions. Although environmental point sources such as landfill sites or hot springs have been characterised, only limited knowledge is available on how widespread the formation of volatile methylated arsenic compounds are in the environment. Here we studied the atmospheric stability of the different arsines and quantified their oxidation products in atmospheric particulate matter (PM(10)) in two locations in Argentina. The atmospheric half-life of the arsines range from 19 weeks for AsH(3) to 2 d for trimethylarsine (TMAs) at 20 degrees C in the dark, while during simulated daytime conditions the stability is reduced for all arsines and in particular for the methylated arsines by three orders of magnitude which suggests that TMAs can only be dispersed at night. At both locations the arsenic concentration was in all samples below 1 ng As m(-3), which is considered as rural background for arsenic. The oxidation products, i.e. methylarsonate (MA), dimethylarsinate (DMA) and trimethylarsine oxide (TMAO) were identified by using HPLC-ICP-MS/ES-MS in more than 90% of the 49 PM(10) samples taken from 8 sampling points at the two geographically different locations. TMAO was the predominate organoarsenicals in both locations (66 and 69%, respectively) while DMA was determined to be between 13 and 19% of all organoarsenicals at the two locations. The concentration of the organoarsenicals ranged from 4 to 60 pg As as TMAO m(-3), while the maximum concentration for DMA and MA were 16 and 6 pg As m(-3), respectively. No difference in terms of the concentration or distribution of the organoarsenicals in the PM(10) samples was identified as significant. Since the two locations were different in climate and industrial impact and sampled in different seasons, these data suggest that methylated arsenicals do occur as background chemicals in the environment. Due to the low atmospheric stability of the methylated arsines, it is suggested that biovolatilization of arsenic as methylated arsines is a widespread phenomenon. More studies however are necessary to identify the major sources and determine the flux of the volatilization process in order to determine whether or not the process has environmental significance.


Assuntos
Arsênio/química , Arsenicais/química , Monitoramento Ambiental/métodos , Material Particulado/química , Argentina , Atmosfera , Meia-Vida , Espectrometria de Massas , Oxirredução
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...